Scedosporium apiospermum lectin 1 (SapL1) (SapL1)

SapL1 (Scedosporium apiospermum lectin 1) is a fucose-binding lectin produced by the opportunistic fungal pathogen Scedosporium apiospermum [1, 6]. It is a structural homolog of the FleA lectin from Aspergillus fumigatus and plays a critical role in the early stages of infection by mediating the adhesion of fungal conidia to fucosylated glycoconjugates on human bronchial epithelial cells [2, 17]. Scedosporium apiospermum is an emerging pathogen particularly dangerous to immunocompromised individuals and patients with cystic fibrosis, and it is notably resistant to most existing antifungal drugs [4, 6]. Consequently, SapL1 has been identified as a promising therapeutic target for the development of antiadhesive 'glycodrugs' or carbohydrate mimics [1, 19]. These agents aim to block the interaction between the lectin and host tissues, preventing colonization without exerting the selective pressure that leads to drug resistance [6, 19]. Research into SapL1 includes detailed structural characterization to guide the design of high-affinity inhibitors [1, 17].

Other names

SapL1Fucose-binding lectin SapL1SAPIO_CDS9261A0A084FYP2

Antiadhesive therapy by blocking the lectin's binding to host fucosylated glycoconjugates, thereby preventing fungal colonization and infection [1, 6].